RMD
ResMed Inc. Healthcare - Medical Instruments & Supplies Investor Relations →
ResMed Inc. (RMD) closed at $188.63 as of 2026-06-19, trading 12.8% below its 200-week moving average of $216.32. This places RMD in the extreme value zone. The stock is currently moving closer to the line, down from -10.0% last week. With a 14-week RSI of 26, RMD is in oversold territory.
Trading volume is running at 1.5x of its 14-week average, which is in the normal range. The balance between buying and selling volume (0.97 ratio) is neutral — neither side is clearly dominating.
Over the past 1572 weeks of data, RMD has crossed below its 200-week moving average 13 times. On average, these episodes lasted 12 weeks. Historically, investors who bought RMD at the start of these episodes saw an average one-year return of +30.4%.
With a market cap of $27.4 billion, RMD is a large-cap stock. The company generates a free cash flow yield of 5.3%, which is healthy. Return on equity stands at 25.2%, indicating strong profitability. The stock trades at 4.2x book value.
RMD passes our Buffett quality screen: high return on equity, low debt, and positive free cash flow.
Over the past 30.2 years, a hypothetical investment of $100 in RMD would have grown to $21165, compared to $1881 for the S&P 500. That represents an annualized return of 19.4% vs 10.2% for the index — confirming RMD as a market-beating investment and the kind of quality company where buying during 200-week moving average touches has historically been rewarded.
Free cash flow has been growing at a 103.8% compound annual rate, with 4 consecutive years of positive cash generation. A business generating more cash every year while trading below its 200-week moving average is exactly the kind of disconnect value investors look for.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: RMD vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After RMD Crosses Below the Line?
Across 13 historical episodes, buying RMD when it crossed below its 200-week moving average produced an average return of +31.6% after 12 months (median +35.0%), compared to +14.2% for the S&P 500 over the same periods. 100% of those episodes were profitable after one year. After 24 months, the average return was +60.4% vs +37.6% for the index.
Each line shows $100 invested at the moment RMD crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Bean Score Experimental
The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. Between earnings dates, FCF is constant — so the score is purely a function of stock price. The levels below show at what prices RMD would reach each dislocation threshold.
Dislocation Price Levels
Prices where RMD's Bean Score would hit each σ threshold. Valid until next earnings report (date TBD — last report: 2026-03-31).
| Level | σ | Price | Signal |
|---|---|---|---|
| Deep Value | +2σ | $190.76 | Unusually cheap — potential buy zone |
| Value | +1σ | $203.40 | Cheap vs. own history |
| Fair Value | +0σ | $217.83 | Historical mean behavior |
| Expensive | -1σ | $234.48 | Expensive vs. own history |
| Deep Expensive | -2σ | $253.87 | Unusually expensive — potential trim zone |
Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end
Signal Accuracy Collecting Data
The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"
Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are reference points for identifying potential swing trade opportunities, not buy/sell signals. FCF values update quarterly with earnings; between reports, all movement is price-driven.
Dislocation Scores Experimental
Each score measures deviation from RMD's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.
Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. They are starting points for research, not buy or sell signals. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.
Historical Touches
RMD has crossed below its 200-week MA 13 times with an average 1-year return of +30.4% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| May 1996 | May 1996 | 1 | 0.9% | +55.6% | +26944.7% |
| May 2002 | Aug 2002 | 14 | 21.4% | +25.3% | +3017.3% |
| Aug 2002 | Oct 2002 | 9 | 15.5% | +39.2% | +2834.0% |
| Nov 2002 | Apr 2003 | 21 | 13.5% | +20.3% | +2716.3% |
| Jun 2008 | Aug 2008 | 8 | 11.4% | +4.8% | +1092.2% |
| Oct 2008 | Feb 2009 | 17 | 23.1% | +34.9% | +1246.3% |
| Feb 2009 | Aug 2009 | 24 | 22.7% | +40.7% | +1017.2% |
| Nov 2011 | Jan 2012 | 8 | 4.3% | +63.5% | +813.1% |
| Jul 2023 | Apr 2024 | 38 | 34.8% | +26.1% | +8.4% |
| May 2024 | Jun 2024 | 1 | 1.0% | +19.7% | -6.9% |
| Jun 2024 | Jul 2024 | 6 | 8.4% | +24.4% | -6.6% |
| Mar 2025 | Apr 2025 | 3 | 4.9% | +10.2% | -7.0% |
| Apr 2026 | Ongoing | 8+ | 12.8% | Ongoing | -7.7% |
| Average | 12 | — | +30.4% | — |
Frequently Asked Questions
Is RMD below its 200-week moving average?
Yes. As of 2026-06-19, ResMed Inc. (RMD) is trading 12.8% below its 200-week moving average of $216.32. The current price is $188.63.
What is RMD's 200-week moving average price?
ResMed Inc.'s 200-week moving average is $216.32 as of 2026-06-19. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when RMD drops below its 200-week moving average?
RMD has crossed below its 200-week moving average 13 times in our data. On average, buying at that moment produced a one-year return of +30.4%. These dips have historically been decent entry points. These episodes lasted 12 weeks on average.
Is RMD a good value right now?
Here's what our data says about RMD as of 2026-06-19: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 26 (oversold). Free cash flow yield is 5.3%. Return on equity is 25.2%. Price-to-book is 4.2x. This is not a buy or sell recommendation — always do your own research.
How does RMD compare to the S&P 500?
Over the past 30.2 years, $100 invested in RMD would have grown to $21165, compared to $1881 for the S&P 500. That's 19.4% annualized vs 10.2% for the index. RMD has outperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-06-19